RATIONALE: Multiple infections with different strains of Mycobacterium tuberculosis may occur in settings where the infection pressure is high. The relevance of mixed infections for the patient, clinician, and control program remains unclear. OBJECTIVES: This study aimed to describe reinfection and mixed infection as underlying mechanisms of changing drug-susceptibility patterns in serial sputum cultures. METHODS: Serial M. tuberculosis sputum cultures from patients diagnosed with multi-drug-resistant (MDR) tuberculosis were evaluated by phenotypic drug-susceptibility testing and mutation detection methods. Genotypic analysis was done by IS6110 DNA fingerprinting and a novel strain-specific polymerase chain reaction amplification method. MEASUREMENTS AND MAIN RESULTS: DNA fingerprinting analysis of serial sputum cultures from 48 patients with MDR tuberculosis attributed 10 cases to reinfection and 1 case to mixed infection. In contrast, strain-specific polymerase chain reaction amplification analysis in 9 of the 11 cases demonstrated mixed infection in 5 cases, reinfection in 3 cases, and laboratory contamination in 1 case. Analysis of clinical data suggests that first-line therapy can select for a resistant subpopulation, whereas poor adherence or second-line therapy resulted in the reemergence of the drug-susceptible subpopulations. CONCLUSIONS: We have shown that, in some patients with MDR tuberculosis, mixed infection may be responsible for observations attributed to reinfection by DNA fingerprinting. We conclude that treatment and adherence determines which strain is dominant. We hypothesize that treatment with second-line drugs may lead to reemergence of the drug-susceptible strain in patients with mixed infection.
RATIONALE: Multiple infections with different strains of Mycobacterium tuberculosis may occur in settings where the infection pressure is high. The relevance of mixed infections for the patient, clinician, and control program remains unclear. OBJECTIVES: This study aimed to describe reinfection and mixed infection as underlying mechanisms of changing drug-susceptibility patterns in serial sputum cultures. METHODS: Serial M. tuberculosis sputum cultures from patients diagnosed with multi-drug-resistant (MDR) tuberculosis were evaluated by phenotypic drug-susceptibility testing and mutation detection methods. Genotypic analysis was done by IS6110 DNA fingerprinting and a novel strain-specific polymerase chain reaction amplification method. MEASUREMENTS AND MAIN RESULTS: DNA fingerprinting analysis of serial sputum cultures from 48 patients with MDR tuberculosis attributed 10 cases to reinfection and 1 case to mixed infection. In contrast, strain-specific polymerase chain reaction amplification analysis in 9 of the 11 cases demonstrated mixed infection in 5 cases, reinfection in 3 cases, and laboratory contamination in 1 case. Analysis of clinical data suggests that first-line therapy can select for a resistant subpopulation, whereas poor adherence or second-line therapy resulted in the reemergence of the drug-susceptible subpopulations. CONCLUSIONS: We have shown that, in some patients with MDR tuberculosis, mixed infection may be responsible for observations attributed to reinfection by DNA fingerprinting. We conclude that treatment and adherence determines which strain is dominant. We hypothesize that treatment with second-line drugs may lead to reemergence of the drug-susceptible strain in patients with mixed infection.
Authors: Darío García de Viedma; Mercedes Marín; Susana Hernangómez; Marisol Díaz; María Jesús Ruiz Serrano; Luis Alcalá; Emilio Bouza Journal: Arch Intern Med Date: 2002-09-09
Authors: C R Braden; G P Morlock; C L Woodley; K R Johnson; A C Colombel; M D Cave; Z Yang; S E Valway; I M Onorato; J T Crawford Journal: Clin Infect Dis Date: 2001-08-06 Impact factor: 9.079
Authors: Madalene Richardson; Nora M Carroll; Erica Engelke; Gian D Van Der Spuy; Faeeza Salker; Zahn Munch; Robert P Gie; Robin M Warren; Nulda Beyers; Paul D Van Helden Journal: J Clin Microbiol Date: 2002-08 Impact factor: 5.948
Authors: Robin M Warren; Thomas C Victor; Elizabeth M Streicher; Madalene Richardson; Nulda Beyers; Nicolaas C Gey van Pittius; Paul D van Helden Journal: Am J Respir Crit Care Med Date: 2003-12-30 Impact factor: 21.405
Authors: Yurena Navarro; Marta Herranz; Laura Pérez-Lago; Miguel Martínez Lirola; Maria Jesús Ruiz-Serrano; Emilio Bouza; Darío García de Viedma Journal: J Clin Microbiol Date: 2011-09-28 Impact factor: 5.948
Authors: Ted Cohen; Paul D van Helden; Douglas Wilson; Caroline Colijn; Megan M McLaughlin; Ibrahim Abubakar; Robin M Warren Journal: Clin Microbiol Rev Date: 2012-10 Impact factor: 26.132
Authors: Yingda L Xie; Soumitesh Chakravorty; Derek T Armstrong; Sandra L Hall; Laura E Via; Taeksun Song; Xing Yuan; Xiaoying Mo; Hong Zhu; Peng Xu; Qian Gao; Myungsun Lee; Jongseok Lee; Laura E Smith; Ray Y Chen; Joon Sung Joh; YoungSoo Cho; Xin Liu; Xianglin Ruan; Lili Liang; Nila Dharan; Sang-Nae Cho; Clifton E Barry; Jerrold J Ellner; Susan E Dorman; David Alland Journal: N Engl J Med Date: 2017-09-14 Impact factor: 91.245